VWF, von Willebrand factor, 7450

N. diseases: 498; N. variants: 158
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Purpura, Thrombotic Thrombocytopenic
0.100 GeneticVariation disease BEFREE We report the results of 10 years of prophylactic fresh-frozen plasma (FFP) infusion therapy in a 14-year-old girl with chronic relapsing thrombotic thrombocytopenic purpura (TTP), in whom a severe congenital von Willebrand factor (VWF)-cleaving protease deficiency has been documented. 11380451 2001
Purpura, Thrombotic Thrombocytopenic
0.100 AlteredExpression disease BEFREE We investigated whether VWF-HMWM level at acute phase of TTP could be a predictive factor for morbidity. 31330376 2019
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE We conducted this study to examine if vWF is involved in the increased platelet retention in TTP. 9423794 1997
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE Ultra-large vWF strings remain uncleaved after endothelial cell secretion and anchorage, bind to platelets and form microthrombi, leading to the clinical manifestations of TTP. 28382967 2017
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE Together, these findings shed new light on the potential roles played by ADAMTS13 and VWF in TTP, endotoxemia, and normal hemostasis. 18083848 2008
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE This review discusses potentials of using recombinant ADAMTS-13 and VWF-blocking agents as therapeutics for TTP and other acquired ADAMTS-13 deficiencies. 22022775 2012
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE This observation led to the recognition that UL vWF multimers precipitate the thrombotic occlusion of arterioles, a feature that characterizes TTP. 12656756 2003
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE This article reviews the role of this cleavage in regulating vWF-platelet interaction and proposes a scheme for understanding how a deficiency of ADAMTS13 results in the development of microthrombi in patients with thrombotic thrombocytopenic purpura. 12615692 2003
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE These findings support the view that vWF proteolysis is critical in regulating vWF-platelet interaction and set the stage for improving the diagnosis and treatment of thrombotic thrombocytopenic purpura. 12395148 2002
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE There are several distinct pathophysiologies leading to microangiopathic hemolysis, ranging from decreased degradation of von Willebrand factor as seen in thrombotic thrombocytopenic purpura (TTP) to endothelial damage facilitated by Escherichia coli shiga toxin or complement dysregulation, seen in shiga toxin-related hemolytic-uremic syndrome (Stx-HUS) and complement-mediated TMA (also called atypical hemolytic-uremic syndrome), respectively. 28447417 2017
Purpura, Thrombotic Thrombocytopenic
0.100 AlteredExpression disease BEFREE The regulation of VWF multimer size is essential in preventing spontaneous microvascular platelet clumping, a central pathophysiologic finding in thrombotic thrombocytopenic purpura (TTP). 23233642 2012
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE The present case report described a patient with thrombotic thrombocytopenic purpura (TTP), who presented to the China-Japan Union Hospital of Jilin University (Changchun, China), and the changes in plasma von Willebrand factor (vWF) and vWF cleaving protease (vWF-cp) observed during treatment. 29250148 2018
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE The presence of unusually large multimers of von Willebrand factor (VWF) is thought to be a major pathogenic factor for thrombotic thrombocytopenic purpura (TTP). 15662617 2005
Purpura, Thrombotic Thrombocytopenic
0.100 GeneticVariation disease BEFREE The moderate activity of ADAMTS-13-P475S for shear-treated VWF is sufficient to prevent thrombotic thrombocytopenic purpura (TTP) onset. 23621748 2013
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE The metalloprotease ADAMTS-13 cleaves von Willebrand factor (VWF), and is absent or severely reduced in the plasma of patients with thrombotic thrombocytopenia purpura (TTP). 14652658 2003
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE The identification of antibodies against a plasma metalloproteinase responsible for cleaving ultralarge von Willebrand factor multimers in thrombotic thrombocytopenic purpura has been followed by the elucidation of the identity of the proteinase. 12105394 2002
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE The deficiency of ADAMTS13 leaves unchecked the hyperadhesive vWF unfolded under high shear stress in the microvessels, resulting in the formation of platelet thrombi, which in turn causes TTP. 16388413 2005
Purpura, Thrombotic Thrombocytopenic
0.100 GeneticVariation disease BEFREE The congenital or acquired deficiency of the von Willebrand factor (VWF) cleaving protease, ADAMTS-13 has been specifically associated with a diagnosis of thrombotic thrombocytopenic purpura (TTP), a microangiopathy characterized by the formation of occlusive platelet thrombi. 15521921 2004
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE Severely deficient activity of the von Willebrand Factor (VWF) cleaving metalloprotease, ADAMTS13, is associated with thrombotic thrombocytopenic purpura (TTP). 16807643 2006
Purpura, Thrombotic Thrombocytopenic
0.100 GeneticVariation disease BEFREE Severe deficiency of the von Willebrand factor (VWF)-cleaving protease ADAMTS13 can lead to thrombotic thrombocytopenic purpura (TTP), a disease associated with the widespread formation of platelet-rich thrombi in many organs. 14976043 2004
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE Severe deficiency of the von Willebrand Factor (VWF)-cleaving proteinase, ADAMTS13, is associated with the development of thrombotic thrombocytopenic purpura (TTP). 14512317 2004
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE Severe deficiency of ADAMTS13, a von Willebrand factor (VWF)-cleaving metalloprotease, causes thrombotic thrombocytopenic purpura. 17426255 2007
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE Severe deficiency of von Willebrand factor (VWF)-cleaving protease (ADAMTS-13) activity (<5% of normal) is a specific finding for acute idiopathic thrombotic thrombocytopenic purpura (TTP), a disorder that presents as thrombocytopenia, microangiopathic hemolytic anemia, and often organ dysfunction such as neurological disturbances or renal failure, and fever. 14727262 2004
Purpura, Thrombotic Thrombocytopenic
0.100 Biomarker disease BEFREE Recent studies on the relationship between UL-vWFMs and vWF-CPase, together with its autoantibody (inhibitor) have brought about a clear discrimination between thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. 11843286 2002
Purpura, Thrombotic Thrombocytopenic
0.100 GeneticVariation disease BEFREE Recent studies have found autoimmune inhibitors or genetic mutations of a von Willebrand factor (VWF) cleaving metalloprotease ADAMTS13 in patients with TTP. 16760911 2006